NCT05370755View on ClinicalTrials.gov

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

January 31, 2026

Conditions

Patients With Advanced Solid Tumors

Interventions

DRUG

ICP-189

Administered orally

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY